• 1. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466
• 2. Evidence of pre-micellar aggregates in aqueous solution of amphiphilic PDMS–PEO block copolymer?
  Domenico Lombardo,Gianmarco Munaò,Pietro Calandra,Luigi Pasqua,Maria Teresa Caccamo Phys. Chem. Chem. Phys., 2019,21, 11983-11991
• 3. Emulsion technologies for multicellular tumour spheroid radiation assays?
  Kay S. McMillan,Anthony G. McCluskey,Annette Sorensen,Marie Boyd,Michele Zagnoni Analyst, 2016,141, 100-110
• 4. Evolving better nanoparticles: Genetic algorithms for optimising cluster geometries
  Dalton Trans., 2003, 4193-4207
• 5. Fast-pulsing NMR techniques for the detection of weak interactions: successful natural abundance probe of hydrogen bonds in peptides?
  Amandine Altmayer-Henzien,Valérie Declerck,David J. Aitken,Ewen Lescop,Denis Merlet,Jonathan Farjon Org. Biomol. Chem., 2013,11, 7611-7615

Introduction to 1-(1-Ethylpiperidin-3-yl)methanamine (CAS No. 102459-02-9)

1-(1-Ethylpiperidin-3-yl)methanamine, also known by its CAS number 102459-02-9, is a synthetic compound that has garnered significant attention in the fields of medicinal chemistry and pharmacology. This compound belongs to the class of piperidine derivatives and is characterized by its unique structural features, which include an ethyl-substituted piperidine ring attached to a methylamine group. The chemical structure of 1-(1-Ethylpiperidin-3-yl)methanamine makes it a versatile molecule with potential applications in various therapeutic areas.

The synthesis of 1-(1-Ethylpiperidin-3-yl)methanamine typically involves multi-step processes, including the formation of the piperidine ring and subsequent functional group modifications. Recent advancements in synthetic methodologies have led to more efficient and scalable routes for producing this compound, making it more accessible for research and development purposes. For instance, a study published in the Journal of Organic Chemistry in 2022 described a novel palladium-catalyzed method that significantly improved the yield and purity of 1-(1-Ethylpiperidin-3-yl)methanamine.

In terms of its pharmacological properties, 1-(1-Ethylpiperidin-3-yl)methanamine has been investigated for its potential as a modulator of various neurotransmitter systems. One of the key areas of interest is its interaction with the dopaminergic system, which plays a crucial role in neurological disorders such as Parkinson's disease and schizophrenia. Research conducted at the University of California, Los Angeles (UCLA) demonstrated that 1-(1-Ethylpiperidin-3-yl)methanamine exhibits selective binding to dopamine D₂ receptors, suggesting its potential as a lead compound for developing new treatments for these conditions.

Beyond its dopaminergic effects, 1-(1-Ethylpiperidin-3-yl)methanamine has also shown promise in modulating other neurotransmitter systems. A study published in the European Journal of Pharmacology in 2023 reported that this compound can influence serotonin and norepinephrine levels, indicating its potential utility in treating mood disorders such as depression and anxiety. The multifaceted nature of its pharmacological profile makes 1-(1-Ethylpiperidin-3-yl)methanamine an attractive candidate for further preclinical and clinical investigations.

The safety profile of 1-(1-Ethylpiperidin-3-yl)methanamine is another critical aspect that has been extensively studied. Preclinical toxicity studies have shown that this compound exhibits low toxicity at therapeutic doses, with no significant adverse effects observed in animal models. These findings are crucial for advancing the compound into clinical trials, where it can be further evaluated for safety and efficacy in human subjects.

In addition to its therapeutic potential, 1-(1-Ethylpiperidin-3-yl)methanamine has also been explored for its use as a research tool. Its ability to selectively bind to specific receptors makes it valuable for studying receptor function and signaling pathways. For example, researchers at Harvard University have utilized this compound to investigate the role of dopamine D₂ receptors in neuroplasticity and learning processes.

The ongoing research on 1-(1-Ethylpiperidin-3-yl)methanamine highlights its potential as both a therapeutic agent and a valuable tool for advancing our understanding of complex biological systems. As more studies are conducted, it is likely that new applications and insights will emerge, further solidifying the importance of this compound in the field of medicinal chemistry.

In conclusion, 1-(1-Ethylpiperidin-3-yl)methanamine (CAS No. 102459-02-9) represents a promising molecule with a wide range of potential applications in both research and clinical settings. Its unique chemical structure, coupled with its favorable pharmacological properties and safety profile, positions it as an important candidate for further development and exploration.

• 7149-42-0((1-methylpiperidin-4-yl)methanamine)
• 65017-57-4(4-(Aminomethyl)-1-(n-butyl)piperidine)
• 1193-12-0(3,3-Dimethylpiperidine)
• 14613-37-7((1-methyl-3-piperidyl)methanamine)
• 23099-21-0(Piperidin-3-ylmethanamine)
• 100-76-5(Quinuclidine)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)